417 related articles for article (PubMed ID: 24699471)
1. Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine.
Daley MF; Yih WK; Glanz JM; Hambidge SJ; Narwaney KJ; Yin R; Li L; Nelson JC; Nordin JD; Klein NP; Jacobsen SJ; Weintraub E
Vaccine; 2014 May; 32(25):3019-24. PubMed ID: 24699471
[TBL] [Abstract][Full Text] [Related]
2. Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study.
Nelson JC; Yu O; Dominguez-Islas CP; Cook AJ; Peterson D; Greene SK; Yih WK; Daley MF; Jacobsen SJ; Klein NP; Weintraub ES; Broder KR; Jackson LA
Am J Epidemiol; 2013 Jan; 177(2):131-41. PubMed ID: 23292957
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
[TBL] [Abstract][Full Text] [Related]
4. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
[TBL] [Abstract][Full Text] [Related]
5. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
6. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
7. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
[TBL] [Abstract][Full Text] [Related]
8. Post-marketing surveillance to assess the safety and tolerability of a combined diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV) in Korean children.
Lee SM; Kim SJ; Chen J; Song R; Kim JH; Devadiga R; Kim YK
Hum Vaccin Immunother; 2019; 15(5):1145-1153. PubMed ID: 30668217
[TBL] [Abstract][Full Text] [Related]
9. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
Johns TL; Hutter GE
Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476
[TBL] [Abstract][Full Text] [Related]
10. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.
Klein NP; Weston WM; Kuriyakose S; Kolhe D; Howe B; Friedland LR; Van Der Meeren O
Vaccine; 2012 Jan; 30(3):668-74. PubMed ID: 22064267
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the tolerability of an acellular pertussis-containing vaccine given as the fifth booster dose in differently primed children.
Kemmeren JM; Timmer SS; van der Maas NA; de Melker HE
Vaccine; 2011 Jun; 29(26):4373-7. PubMed ID: 21514347
[TBL] [Abstract][Full Text] [Related]
13. Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers.
Hansen J; Timbol J; Lewis N; Pool V; Decker MD; Greenberg DP; Klein NP
Vaccine; 2016 Jul; 34(35):4172-4179. PubMed ID: 27373595
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of adverse events following vaccination in the French armed forces, 2011-2012.
Mayet A; Duron S; Meynard JB; Koeck JL; Deparis X; Migliani R
Public Health; 2015 Jun; 129(6):763-8. PubMed ID: 25890634
[TBL] [Abstract][Full Text] [Related]
16. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
Tregnaghi M; Zambrano B; Santos-Lima E
Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
[TBL] [Abstract][Full Text] [Related]
17. Vaccine safety implications of Ontario, Canada's switch from DTaP-IPV to Tdap-IPV for the pre-school booster.
Klar S; Harris T; Wong K; Fediurek J; Deeks SL
Vaccine; 2014 Nov; 32(48):6360-3. PubMed ID: 25252195
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of
Puente Gómez I; Verheust C; Hanssens L; Dolhain J
Expert Rev Vaccines; 2020 Aug; 19(8):771-779. PubMed ID: 32729745
[TBL] [Abstract][Full Text] [Related]
19. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children.
Pancharoen C; Chotpitayasunondh T; Chuenkitmongkol S; Ortiz E
Southeast Asian J Trop Med Public Health; 2012 May; 43(3):687-98. PubMed ID: 23077849
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M
Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
